SLC5A2 and type 2 diabetes mellitus: In another recent trial, the superior efficacy of insulin degludec/liraglutide vs. insulin glargine (IGlar U100) as add-on to SGLT2 inhibitors ± oral antidiabetic drug therapy in patients with type 2 diabetes (DUAL IX) trial, patients already receiving a SGLT2 inhibitor with or without other oral antidiabetic drugs were randomized to be treated with an injectable combination of insulin degludec and liraglutide (IDegLira) or insulin glargine (IGlar) alone [39].